包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限自公司董事会审议 通过回购股份方案之日起12个月内。因公司实施2024年度权益分派，公司本次回 购价格上限由不超过人民币8.00元/股(含)调整为不超过人民币7.98元/股(含)。具 体内容详见公司在巨潮资讯网(www.cninfo.com.cn)上披露的《回购股份报告书》 (公告编号：2025-009)、《关于2024年度权益分派实施后调整回购股份价格上限 和数量的公告》（公告编号：2025-049） ...

Core Points - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu, with the theme "Moving Forward with New Initiatives for a Sustainable Future" [1] - Guoen Co., Ltd. received the "2024 Golden Bull Secretary Award," highlighting its achievements in corporate governance and investor relations [1][5] Group 1: Company Overview - Guoen Co., Ltd. operates a vertically integrated industrial platform focused on the large chemical and health industries, implementing a "one body, two wings" development strategy [4] - The company has optimized its industrial structure, developing a comprehensive industrial cluster in new chemical materials, including green petrochemicals, organic polymer modifications, and lightweight components for new energy vehicles [4] - Guoen also holds a controlling stake in Dongbao Biological, which specializes in gelatin and collagen products, forming a diversified enterprise group in the health sector [4] Group 2: Award Significance - The Golden Bull Award is a prestigious evaluation activity organized by China Securities Journal, emphasizing transparency, professionalism, and credibility in the capital market [4] - The award aims to create a platform for authoritative recognition and brand display for listed companies, promoting healthy development within the capital market [4][5] - The awards include categories such as "Most Investment Value Award," "Golden Bull Outstanding Entrepreneur Award," and "Golden Bull Secretary Award," recognizing excellence in corporate governance and investor relations [5]

Core Viewpoint - Dongbao Biological is a leading gelatin and collagen producer in China, with significant technological barriers and a notable market share in the industry [1] Group 1: Business Overview - Dongbao Biological was established on March 12, 1997, and listed on the Shenzhen Stock Exchange on July 6, 2011, with its registered and operational base in Baotou, Inner Mongolia [1] - The company's main business includes the research, production, and sales of gelatin products and low molecular weight collagen, categorized under the pharmaceutical and biological industry [1] Group 2: Financial Performance - For Q3 2025, Dongbao Biological reported revenue of 533 million yuan, ranking 22nd among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was 48.447 million yuan, placing the company 20th in the industry, while the top performer, Tonghua Dongbao, achieved a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Dongbao Biological's debt-to-asset ratio was 32.50%, higher than the industry average of 26.88% and improved from 36.68% in the previous year [3] - The company's gross profit margin was 24.53%, an increase from 22.62% year-on-year, but still below the industry average of 70.17% [3] Group 4: Executive Compensation - The chairman, Wang Aiguo, received a salary of 9,600 yuan for 2024, unchanged from the previous year, while the general manager, Liu Fang, earned 745,100 yuan, a decrease of 32,000 yuan from 2023 [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.01% to 20,500, while the average number of circulating A-shares held per shareholder increased by 6.39% to 28,800 [5]

Core Insights - Dongbao Bio (300239.SZ) reported its Q3 2025 results, revealing that as of October 28, 2025, seven institutional investors held a total of 205 million shares, representing 34.59% of the company's total equity. This marks a decrease of 0.48 percentage points in institutional ownership compared to the previous quarter [1] Institutional Holdings - The institutional investors include Qingdao Guoen Technology Co., Ltd., Hainan Bainashengyuan Technology Co., Ltd., Shaanxi International Trust Co., Ltd. - Shaanguo Investment Dongbao Bio 2022 Employee Stock Ownership Trust Plan, National Social Security Fund 504 Portfolio, China Lucky Group Co., Ltd., Zhongke Xianxing (Beijing) Asset Management Co., Ltd., and Industrial and Commercial Bank of China - GF Jufeng Mixed Securities Investment Fund [1] - The total institutional ownership decreased by 0.48 percentage points from the last quarter [1] Public Fund Holdings - One public fund, GF Jufeng Mixed A, increased its holdings during this period, with an increase ratio of 0.29% [1] - A total of 35 public funds did not disclose their holdings this quarter, including Zhongzheng 2000, Huitianfu Zhongzheng 500 Index Enhanced A, Jiashi Zhongzheng Vaccine and Biotechnology ETF, GF Consumer Selected Mixed A, and Bodao Consumer Intelligent Navigation A [1] Social Security Fund Holdings - One social security fund, the National Social Security Fund 504 Portfolio, reduced its holdings by 0.58% compared to the previous quarter [1]

Company Overview - Dongbao Biological (SZ 300239) announced the convening of its 14th meeting of the 9th Board of Directors on October 28, 2025, to review the proposal for the "2025 Third Quarter Report" [1] - The company's revenue composition for the year 2024 is entirely from biological and biochemical products, accounting for 100.0% [1] - As of the report, Dongbao Biological has a market capitalization of 3.4 billion yuan [1] Industry Context - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [1] - This shift indicates the emergence of a "slow bull" market pattern, suggesting a new phase in market dynamics [1]

第九届董事会第十四次会议决议公告 包头东宝生物技术股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-067 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 2025 年第三季度报告的内容真实、准确、完整地反映了公司 2025 年第三季 度的实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏，报告的编制 和审核程序符合法律、行政法规的要求，符合中国证监会和深交所的相关规定。 公司董事会同意议案内容。 表决结果：7 票同意，0 票反对，0 票弃权。 本议案获得表决通过。公司第九届董事会审计委员会审议通过了本议案。具 体内容详见同日披露于巨潮资讯网的《2025 年第三季度报告》(2025-068)。 三、备查文件 1、第九届董事会第十四次会议决议； 2、深圳证券交易所要求的其他文件。 特此公告。 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第十四次 会议 ...

Financial Performance - The company's revenue for Q3 2025 was ¥163,742,176.20, a decrease of 13.29% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥11,482,207.82, down 23.10% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥8,620,812.63, reflecting a decline of 34.37% compared to the previous year[10]. - Total operating revenue for the current period was ¥532,797,977.19, a decrease of approximately 16% compared to ¥633,112,065.92 in the previous period[25]. - Net profit for the current period is 48,447,635.50, a decrease of 32.3% compared to 71,535,188.56 in the previous period[26]. - Operating profit for the current period is 55,378,873.91, down from 82,596,541.20, reflecting a decline of 33.0%[26]. - Total comprehensive income for the current period is 48,447,635.50, down 32.3% from 71,535,188.56 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,543,840,091.48, a decrease of 3.09% from the end of the previous year[5]. - Total liabilities decreased to ¥826,649,536.43 from ¥885,496,289.52, a decline of about 6.6%[24]. - The total assets decreased to ¥2,543,840,091.48 from ¥2,624,919,556.21, reflecting a reduction of about 3.1%[24]. - Long-term equity investments decreased to ¥13,914,675.17 from ¥15,428,520.01, a decline of approximately 9.8%[23]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥61,417,693.72, an increase of 109.82%[5]. - The net cash flow from operating activities increased to ¥61,417,693.72, a rise of 109.82% compared to the previous period's ¥29,272,022.08, primarily due to higher cash received from sales[14]. - Cash flow from operating activities increased to 61,417,693.72, compared to 29,272,022.08 in the previous period, representing a growth of 109.5%[27]. - Cash flow from investing activities resulted in a net outflow of -42,377,549.85, an improvement from -134,567,469.44 in the previous period[28]. - Cash flow from financing activities was -¥18,959,353.05, with a significant increase of 263.36% from the previous period, attributed to higher cash payments for debt repayment and dividends, along with stock buyback activities[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,471, with no preferred shareholders having restored voting rights[16]. - Qingdao Guoen Technology Co., Ltd. held the largest share, owning 21.18% (125,711,022 shares) of the company[16]. - The top ten shareholders collectively hold significant stakes, with the largest shareholder having 21.18% and the smallest in the top ten holding 0.62%[16]. - The company has a repurchase account holding 10,573,400 shares, representing 1.78% of the total share capital[17]. - There were no changes in the number of preferred shareholders or significant changes in the top ten shareholders due to lending or borrowing of shares[18]. - The company reported a total of 3,962,437 restricted shares, with 116,287 shares released during the period[19]. Operating Costs and Expenses - Total operating costs decreased to ¥479,925,097.45 from ¥555,269,833.32, reflecting a reduction of about 13.5%[25]. - The company's net profit margin is under pressure due to increased operating expenses, with research and development expenses rising to ¥18,907,749.32 from ¥16,012,452.92, an increase of about 18%[25]. - Financial expenses increased by 130.70% to ¥1,137,785.38, primarily due to higher interest expenses[11]. Inventory and Receivables - Accounts receivable decreased to ¥173,096,032.96 from ¥206,201,924.73, representing a reduction of about 16%[22]. - Inventory increased significantly to ¥420,415,267.14 from ¥354,463,939.10, an increase of approximately 18.6%[22]. - The company's cash and cash equivalents decreased to ¥483,228,383.16 from ¥532,101,881.48, a decline of approximately 9.2%[22]. - The company reported a decrease in total assets impairment losses to -4,747,143.37 from -1,548,347.56, indicating a significant change in asset valuation[26].

Core Viewpoint - Dongbao Biological (300239) clarified on October 24 that its gelatin products are not used in breast enhancement applications [1] Company Summary - Dongbao Biological responded to investor inquiries on an interactive platform regarding the use of its gelatin products [1]

Core Viewpoint - Dongbao Bio has confirmed that its artificial blood plasma gelatin has achieved sales, indicating progress in its product development and market entry [2] Company Summary - Dongbao Bio (300239.SZ) responded to an investor inquiry on October 24, stating that its artificial blood plasma gelatin (Pharmacopoeia gelatin) is now available for sale [2]

Group 1 - The artificial meat concept sector rose by 1.81%, ranking fifth among concept sectors, with 14 stocks increasing in value, including Shuangta Food, which hit the daily limit, and others like Suobao Protein and Haoxiangni showing gains of 6.33%, 3.53%, and 2.66% respectively [1][2] - The main inflow of funds into the artificial meat concept sector was 132 million yuan, with Shuangta Food receiving the highest net inflow of 98.69 million yuan, followed by Suobao Protein and Meiyingsen with net inflows of 46.11 million yuan and 16.86 million yuan respectively [2][3] - The net inflow ratios for Shuangta Food, Suobao Protein, and Meiyingsen were 31.69%, 11.94%, and 8.56% respectively, indicating strong investor interest in these stocks [3] Group 2 - Among the stocks in the artificial meat sector, the top performers included Shuangta Food with a daily increase of 9.98% and a turnover rate of 4.40%, while stocks like Haoxiangni and Dongbao Biological also showed positive performance with increases of 3.53% and 2.66% respectively [3][4] - Conversely, stocks such as Angel Yeast, Fuxiang Pharmaceutical, and Tangrenshen experienced declines of 0.91%, 0.57%, and 0.21% respectively, indicating mixed performance within the sector [1][4]